Ceribell, Inc. (CBLL) stock
CBLLNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30134% above fair value
$25.63−0.34 (-1.31%)
Close on Nov 18, 2026Market cap $983.63MP/E –Yield –
Ceribell free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Ceribell's free cash flow for the twelve months ending Jun 30, 2026 was -$54.72M. For fiscal 2025 it was -$41.58M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$41.58M | – |
| FY2024 | Dec 31, 2024 | -$36.38M | – |
| FY2023 | Dec 31, 2023 | -$30.14M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$12.88M | – |
| Q1 FY2026 | Mar 31, 2026 | -$19.42M | – |
| Q4 FY2025 | Dec 31, 2025 | -$10.95M | – |
| Q3 FY2025 | Sep 30, 2025 | -$11.47M | – |
| Q2 FY2025 | Jun 30, 2025 | -$7.60M | – |
| Q1 FY2025 | Mar 31, 2025 | -$11.55M | – |
| Q4 FY2024 | Dec 31, 2024 | -$10.33M | – |
| Q3 FY2024 | Sep 30, 2024 | -$9.11M | – |
| Q2 FY2024 | Jun 30, 2024 | -$7.30M | – |
| Q1 FY2024 | Mar 31, 2024 | -$9.65M | – |
| Q4 FY2023 | Dec 31, 2023 | -$7.15M | – |
See a number that looks wrong?